Hepatitis C: latest news - GoINPHARMA
Sunday, 24 March 2019 - 18:37

Hepatitis C

Gilead to strengthen hepatitis C portfolio with Vosevi

Gilead strengthens its position in the hepatitis C treatment business by introducing a new product into its portfolio. The California-based group announced yesterday that FDA approved Vosevi (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg tablet) for the 12-week treatment of…

FDA warning: hepatitis C drugs entail risk of HBV reactivation

FDA has detected serious risks for some patients who have been infected with the hepatitis B virus (HBV) and are being treated with DAA (direct-acting antiviral) drugs for hepatitis C (HCV). The US Agency has identified 24 cases of HBV…